Figure S1 PBS Free E7LP NP-E7LP...PBS Free E7LP NP-0 5 10 15 % of CD 1 1b+ F480+ cells (of live...
13
IFNγ TNFα Granzyme B IFNγ TNFα FS-H PBS Free E7LP NP-E7LP 0,021 2,43 10,9 0,066 1,12 2,58 0,1 0,67 2,6 0,042 0,96 3,81 Figure S1
Transcript of Figure S1 PBS Free E7LP NP-E7LP...PBS Free E7LP NP-0 5 10 15 % of CD 1 1b+ F480+ cells (of live...
IFNγ
TNFα
Granzyme B
IFNγ
TNFα
FS-H
PBS Free E7LP NP-E7LP0,021 2,43 10,9
0,066 1,12 2,58
0,1 0,67 2,6
0,042 0,96 3,81
Figure S1
0 5 10 15 200
200
400
600
800
1000
Tum
or s
ize
(mm
3 ) Free E7LPNP-E7LPNP-E7LP 2x
PBS
Days post TC-1 implantation
ns
****
ns
Figure S2
0 10 20 30 40
PBSNP-E7LPNP-E7LP + anti-CD4NP-E7LP + anti-CD8 NP-E7LP + anti-CD4 + anti CD8
Days post TC-1 implantation
Perc
ent s
urvi
val (
%)
0 10 20 300
500
1000
1500
Days post TC-1 implantation
Tum
or s
ize
(mm
3 )
PBS
0 10 20 300
500
1000
1500
Days post TC-1 implantation
Tum
or s
ize
(mm
3 )
NP-E7LP + anti-CD4
0 10 20 300
500
1000
1500
Days post TC-1 implantation
Tum
or s
ize
(mm
3 )
NP-E7LP
0 10 20 300
500
1000
1500
Days post TC-1 implantation
Tum
or s
ize
(mm
3 )
NP-E7LP + anti-CD8
0 10 20 300
500
1000
1500
Days post TC-1 implantation
Tum
or s
ize
(mm
3 )
NP-E7LP + anti-CD4 + anti CD8
0 5 10 15 200
500
1000
1500
Tum
or s
ize
(mm
3 )
ns
ns
****
Days post TC-1 implantation
B
A
CPBSNP-E7LPNP-E7LP + anti-CD4NP-E7LP + anti-CD8 NP-E7LP + anti-CD4 + anti CD8
0
100
25
50
75
Figure S3
0 10 20 30 40 500
500
1000
1500
2000
Days after tumor implantation
Tum
or s
ize
(mm
3) PBS
0 10 20 30 40 500
500
1000
1500
2000 PBSFree E7LPNP-E7LP
Days after tumor implantation
Tum
or s
ize
(mm
3 )
0 10 20 30 40 500
500
1000
1500
2000
Days after tumor implantation
Free E7LP
0 10 20 30 40 500
500
1000
1500
2000
Days after tumor implantation
NP-E7LP
Tum
or s
ize
(mm
3)
Tum
or s
ize
(mm
3)
A
B
****
*** **
**
****
****
****
****
****
************
Figure S4
PBS
Free E
7LP
NP-E7L
P0
5
10
15
20
% o
f CD
8+ a
rea
(o
f DAP
I+ a
rea)
Subcutaneous tumors
**
******
Figure S5
PBS
Free E
7LP
NP-E7L
P0
5
10
15
% o
f CD
11b+
F48
0+ c
ells
(o
f liv
e ce
lls)
PBS
Free E
7LP
NP-E7L
P0
5
10
15
20
25
% o
f CD
11bH
i Ly6
C+
Ly6G
- cel
ls (o
f liv
e ce
lls)
PBS
Free E
7LP
NP-E7L
P0
20
40
60
80
100
% o
f CD
206+
cel
ls(o
f CD
11b+
F48
0+ c
ells
)
PBS
Free E
7LP
NP-E7L
P0
0.5
1.0
1.5
% o
f CD
11bH
i Ly6
C-
Ly6G
+ ce
lls (o
f liv
e ce
lls)
***
***n.s. n.s.
n.s.
n.s.
****n.s. n.s.
*
**n.s.
n.s.****
****
A B
C D
E F
PBS
Free E
7LP
NP-E7L
P0
5
10
15
20
% o
f F4/
80-C
D11
b+C
D11
c+ c
ells
(o
f liv
e ce
lls)
PBS
Free E
7LP
NP-E7L
P0
5
10
15
% o
f F4/
80-C
D11
b-C
D11
c+ c
ells
(o
f liv
e ce
lls)
n.s.
**
****
Figure S6
PBS
Free E
7LP
NP-E7L
P0
5
10
15
20
% o
f CD
8+ a
rea
(of D
API+
are
a)
Intravaginal tumors
**
n.s.
PBS
Free E
7LP
NP-E7L
P0
5
10
15
20
% o
f CD
8+ a
rea
(of D
API+
are
a)
Lung metastases
**
****
A B
Figure S7
0 25 50 750
500
1000
1500
Tum
or s
ize
(mm
3 )
Respo
nse
Stab
le
Relaps
eA
TC1
TC1 rela
pse0.0
0.5
1.0
1.5
2.0B2M
Rel
ativ
e ex
pres
sion
TC1
TC1 rela
pse0.0
0.5
1.0
1.5
2.0E7
Rel
ativ
e ex
pres
sion
TC1
TC1 rela
pse0.00.51.01.52.02.5
TAP1
Rel
ativ
e ex
pres
sion
TC1
TC1 rela
pse0.00.51.01.52.02.5
H2Db
Rel
ativ
e ex
pres
sion
TC1
TC1 rela
pse0.00.51.01.52.02.5
PSMB5R
elat
ive
expr
essi
on *
B
RAHYNIVTFIDDZ7325DZ7326DZ7327DZ7339DZ7340DZ7341DZ7342DZ7343
SequenceRAHYNIVTFRAHYNIVTFRAHYNIVTFRAHYNIVTFRAHYNIVTFRAHYNIVTFRAHYNIVTFRAHYNIVTF
Figure S8
A B C
PBS
Respo
nse
Stable
Relaps
e0
10
20
30
40
% o
f CD
8+ a
rea
(of D
API+
are
a)
CD8
******
***
PBS
Respo
nse
Stable
Relaps
e0
10
20
30St
aini
ng in
tens
ity
ICOS
ns
******
PBS
Respo
nse
Stable
Relaps
e0
10
20
30
40
Stai
ning
inte
nsity
F4/80
**n.s.
**
Figure S9
CD11c MRC1Relapse
F4/8
0
CD11c MRC1Response
F4/8
0
CD11c MRC1PBS (end stage)
F4/8
0
CD11c MRC1Stable
F4/8
0
Figure S10
A B C
PBS
Respo
nse
Stable
Relaps
e0
20
40
60
Stai
ning
inte
nsity
CD11c
*****
*
PBS
Respo
nse
Stable
Relaps
e0
5
10
15
20
25St
aini
ng in
tens
ity
MRC1
**
n.s.
PBS
Respo
nse
Stable
Relaps
e0
10
20
30
40
Stai
ning
inte
nsity
PDL1
**
n.s.
Figure S11
0 5 10 15 200
500
1000
1500
Days post TC-1 implantation
Tum
or s
ize
(mm
3 )
Free E7LPFree E7LP + anti-41BBNP-E7LPNP-E7LP + anti-41BB
Figure S12
Free E
7LP
Free E
7LP +
anti-4
1BB
NP-E7L
P
NP-E7L
P + an
ti-41B
B0
5
10
15
% o
f E7
spec
ific
CD
8 T
cells
(o
f liv
e ce
lls)
*
ns
ns
**
012345
10203040
% o
f IFN
γ+
CD
8 T
cells
(o
f liv
e ce
lls)
*
ns
*
***
0
5
10
15
% o
f 41B
B+ E
7 sp
ecifi
c C
D8
T ce
lls (o
f liv
e ce
lls) *
ns
ns
**
0
10
20
30
40
50
% o
f CD
44+
KLR
G1+
cel
ls
(of E
7 sp
ecifi
c C
D8
T ce
lls)
**** **
ns
0.00.51.01.52.0
2468
10
% o
f TNFα
+ C
D8
T ce
lls
(of l
ive
cells
)
ns
ns
ns
***
0
5
10
15
20
% o
f GIT
R+
E7 s
peci
fic
CD
8 T
cells
(of l
ive
cells
) *
ns
ns
***
0.00.51.01.52.0
2345
% o
f CD
44+
KLR
G1+
E7
spe
cific
CD
8 T
cells
(o
f liv
e ce
lls)
nsns **
***
0246
10203040
% o
f Gra
nzym
eB+
CD
8 T
cells
(of l
ive
cells
) *
ns
ns
**
0.0
0.2
0.4
0.6
0.8
% o
f IC
OS+
E7
spec
ific
CD
8 T
cells
(of l
ive
cells
) ns
ns
ns
**
0.0
0.5
1.0
1.5
% o
f OX4
0+ E
7 sp
ecifi
c C
D8
T ce
lls (o
f liv
e ce
lls) ns
ns
ns
**
0
1000
2000
3000
CD
8/Tr
eg c
ells
ratio
ns
ns
ns
*
** ** * *
A B C D
E F G H
I J K
Free E
7LP
Free E
7LP +
anti-4
1BB
NP-E7L
P
NP-E7L
P + an
ti-41B
B
Free E
7LP
Free E
7LP +
anti-4
1BB
NP-E7L
P
NP-E7L
P + an
ti-41B
B
Free E
7LP
Free E
7LP +
anti-4
1BB
NP-E7L
P
NP-E7L
P + an
ti-41B
B
Free E
7LP
Free E
7LP +
anti-4
1BB
NP-E7L
P
NP-E7L
P + an
ti-41B
B
Free E
7LP
Free E
7LP +
anti-4
1BB
NP-E7L
P
NP-E7L
P + an
ti-41B
B
Free E
7LP
Free E
7LP +
anti-4
1BB
NP-E7L
P
NP-E7L
P + an
ti-41B
B
Free E
7LP
Free E
7LP +
anti-4
1BB
NP-E7L
P
NP-E7L
P + an
ti-41B
B
Free E
7LP
Free E
7LP +
anti-4
1BB
NP-E7L
P
NP-E7L
P + an
ti-41B
B
Free E
7LP
Free E
7LP +
anti-4
1BB
NP-E7L
P
NP-E7L
P + an
ti-41B
B
Free E
7LP
Free E
7LP +
anti-4
1BB
NP-E7L
P
NP-E7L
P + an
ti-41B
B
Figure S13
![Polymer/Nanocrystal Hybrid Solar Cells: Influence of ... · PDF file... [ 4 ] PbS, [ 1,5 ] PbSe ... One of the major challenges with hybrid solar cells is the diffi culty ... sical](https://static.fdocuments.us/doc/165x107/5ab8c59d7f8b9ad5338d3ae7/polymernanocrystal-hybrid-solar-cells-influence-of-4-pbs-15.jpg)
